Figure 12 is a plot of control arm mortality rate during ESA treatment and the four following weeks versus relative risk plotted on a logarithmic scale. This figure is described further in section “Evidence Regarding the Class of Erythropoietic-Stimulating Agents” as follows: “plots the 16-week mortality rate in the control arms (either reported in Bohlius et al. for trials with 12-weeks ESA treatment, or estimated for trials of different length) against the logarithm of on-study relative risk of mortality. The depiction is consistent with a higher relative risk in trials with lower control arm mortality rates. Moreover, when included in a model, control arm mortality modified the relative effect (p=0.002).”

Figure 12Plot of control arm mortality rate during ESA treatment and the four following weeks versus relative risk plotted on a logarithmic scale7

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.